Annual report pursuant to Section 13 and 15(d)

Condensed Consolidated Statement of Equity

v2.4.0.8
Condensed Consolidated Statement of Equity (USD $)
In Thousands, except Share data, unless otherwise specified
Total
OPKO Diagnostics [Member]
FineTech [Member]
Farmadiet [Member]
OURLab [Member]
OPKO Brazil [Member]
Cytochroma [Member]
PROLOR [Member]
Common Stock [Member]
Common Stock [Member]
OPKO Diagnostics [Member]
Common Stock [Member]
FineTech [Member]
Common Stock [Member]
Farmadiet [Member]
Common Stock [Member]
OURLab [Member]
Common Stock [Member]
OPKO Brazil [Member]
Common Stock [Member]
Cytochroma [Member]
Common Stock [Member]
PROLOR [Member]
Treasury
Treasury
OPKO Diagnostics [Member]
Treasury
Farmadiet [Member]
Additional Paid-In Capital
Additional Paid-In Capital
OPKO Diagnostics [Member]
Additional Paid-In Capital
FineTech [Member]
Additional Paid-In Capital
Farmadiet [Member]
Additional Paid-In Capital
OURLab [Member]
Additional Paid-In Capital
OPKO Brazil [Member]
Additional Paid-In Capital
Cytochroma [Member]
Additional Paid-In Capital
PROLOR [Member]
Acumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Noncontrolling Interests
Series D Preferred Stock
Series D Preferred Stock
Common Stock [Member]
Series D Preferred Stock
Additional Paid-In Capital
Notes [Member]
Notes [Member]
Common Stock [Member]
Notes [Member]
Additional Paid-In Capital
Series A Preferred Stock [Member]
Series A Preferred Stock [Member]
Common Stock [Member]
Series A Preferred Stock [Member]
Additional Paid-In Capital
Series A Preferred Stock [Member]
Accumulated Deficit
Series D Preferred Stock [Member]
Series D Preferred Stock [Member]
Common Stock [Member]
Series D Preferred Stock [Member]
Additional Paid-In Capital
Beginning balance at Dec. 31, 2010 $ 23,052               $ 2,554               $ (61)     $ 376,008               $ 2,921 $ (358,379)               $ 9            
Beginning balance, shares at Dec. 31, 2010                 255,412,706               (45,154)                                       897,439            
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                                                                      
Equity-based compensation expense 7,155                                     7,155                                              
Exercise of Common Stock options 984               4                     980                                              
Exercise of Common Stock options, shares                 422,500                                                                    
Exercise of Common Stock warrants 260               29                     231                                              
Exercise of Common Stock warrants, shares                 2,925,894                                                                    
Preferred Stock dividend                                                                         (60)     (60) (4,704)   (4,704)
Conversion of Preferred Stock                                                                         (3) 3     1,742 10 1,732
Conversion of Preferred Stock, shares                                                                         (294,680) 294,680       940,141  
Stock Redeemed or Called During Period, Value (1,507)                                                                       (6)   (1,501)        
Stock Redeemed or Called During Period, Shares                                                                         (602,759)            
Stock Issued During Period, Value, New Issues 104,828               294                     104,534                                              
Stock Issued During Period, Shares, New Issues                 29,397,029                                                                    
Stock Repurchased During Period, Value (7,832)                               (7,832)                                                    
Stock Repurchased During Period, Shares                                 (2,398,740)                                                    
Issuance of Common Stock in connection with acquisition   22,452 17,717             45 36             (199)     22,606 17,681                                          
Issuance of Common Stock in connection with acquisition, shares                   4,494,380 3,615,703             (44,583)                                                  
Purchase Price Adjustment 92                                     92                                              
Net loss attributable to common shareholders before preferred stock dividend (1,283)                                                       (1,283)                            
Net loss attributable to noncontrolling interests 0                                                                                    
Other comprehensive loss (2,014)                                                     (2,014)                              
Ending balance at Dec. 31, 2011 160,882               2,975               (8,092)     524,814               907 (359,722)                            
Ending balance, shares at Dec. 31, 2011                 297,503,033               (2,488,477)                                                    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                                                                      
Equity-based compensation expense 5,131                                     5,131                                              
Exercise of Common Stock options 2,234               10                     2,224                                              
Exercise of Common Stock options, shares                 1,019,967                                                                    
Exercise of Common Stock warrants 45               1                     44                                              
Exercise of Common Stock warrants, shares                 65,015                                                                    
Adjustment of Common Stock Value                 (1)                     1                                              
Adjustment of Common Stock Shares                 (100,000)                                                                    
Issuance of Common Stock in connection with acquisition       805 32,888               71           635       170 32,817                                      
Issuance of Common Stock in connection with acquisition, shares                         7,072,748           195,421                                                
Net loss attributable to common shareholders before preferred stock dividend (29,048)                                                       (29,048)                            
Net loss attributable to noncontrolling interests (492)                                                         (492)                          
Other comprehensive loss 6,449                                                     6,449                              
Ending balance at Dec. 31, 2012 178,894 [1]               3,056               (7,457)     565,201               7,356 (388,770) (492)                          
Ending balance, shares at Dec. 31, 2012                 305,560,763               (2,293,056)                                                    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                                                                      
Equity-based compensation expense 10,983                                     10,983                                              
Exercise of Common Stock options 22,796               92                     22,704                                              
Exercise of Common Stock options, shares 9,254,744               9,244,971                                                                    
Exercise of Common Stock warrants 628               15                     613                                              
Exercise of Common Stock warrants, shares                 1,487,774                                                                    
Preferred Stock dividend                                                             (3,015)   (3,015)                    
Conversion of Preferred Stock                                                             24,386 113 24,273 20,839 24 20,815              
Conversion of Preferred Stock, shares                                                               11,290,320     2,396,145                
Issuance of Common Stock in connection with acquisition           435 146,902 586,643           1 205 637                 434 146,697 586,006                                
Issuance of Common Stock in connection with acquisition, shares                           64,684 20,517,030 63,670,805                                                      
Stock Issued During Period, Value, Deferred Payment       4,435               5             0       4,430                                        
Stock Issued During Period, Share, Contingent Consideration                                     28,993                                                
Stock Issued During Period, Value, Contingent Consideration       337                             95       242                                        
Stock Issued During Period, Share, Deferred Payment                       585,703             0                                                
Net loss attributable to common shareholders before preferred stock dividend (114,407)                                                       (114,407)                            
Net loss attributable to noncontrolling interests (2,939)                                                         (2,939)                          
Other comprehensive loss (3,938)                                     0               (3,938)                              
Ending balance at Dec. 31, 2013 $ 872,979 [1]               $ 4,148               $ (7,362)     $ 1,379,383               $ 3,418 $ (503,177) $ (3,431)                          
Ending balance, shares at Dec. 31, 2013                 414,818,195               2,264,063                                                    
[1] As of December 31, 2013 and 2012, total assets include $6.7 million and $5.6 million, respectively, and total liabilities include $10.4 million and $5.5 million, respectively related to SciVac Ltd (“SciVac”), previously known as SciGen (I.L.) Ltd, a consolidated variable interest entity. SciVac’s consolidated assets are owned by SciVac and the holders of SciVac’s consolidated liabilities have no recourse against us. Refer to Note 3.